Last $4.34 USD
Change Today -0.07 / -1.59%
Volume 204.9K
OSUR On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 4:00 PM 05/24/13 All times are local (Market data is delayed by at least 15 minutes).

orasure technologies inc (OSUR) Snapshot

Open
$4.39
Previous Close
$4.41
Day High
$4.40
Day Low
$4.31
52 Week High
07/9/12 - $14.01
52 Week Low
04/26/13 - $4.24
Market Cap
241.0M
Average Volume 10 Days
276.6K
EPS TTM
$-0.40
Shares Outstanding
55.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ORASURE TECHNOLOGIES INC (OSUR)

Related News

No related news articles were found.

orasure technologies inc (OSUR) Related Businessweek News

No Related Businessweek News Found

orasure technologies inc (OSUR) Details

OraSure Technologies, Inc. develops, manufactures, and markets oral fluid diagnostic products and specimen collection devices using its proprietary oral fluid technologies. Its diagnostic products include tests that are performed on a rapid basis at the point of care; and tests, which are processed in a laboratory. The principal products comprise OraQuick ADVANCE HIV-1/2, OraQuick In-Home HIV Test, OraQuick HCV, OraSure QuickFlu rapid flu A&B test, OraSure, Oragene DX, Oragene DNA, Oragene DISCOVER, Oragene RNA, ORAcollect, OMNIgene DISCOVER, Performagene LIVESTOCK and Oragene ANIMAL, Intercept, MICRO-PLATE DOA Assays, Homogeneous DOA Assays, and professional and over-the-counter Cryosurgical Systems. In addition, the company, through its subsidiary, DNA Genotek Inc., manufactures and sell kits used to collect, stabilize, and store samples of genetic material for molecular testing in the academic research, clinical genetic testing, pharmacogenomics, personalized medicine, and animal and livestock genetics markets. Its OraGene DNA sample collection kit provides an all-in-one system for the collection, stabilization, and transportation of DNA from human saliva. Further, the company offers medical devices used for the removal of benign skin lesions by cryosurgery or freezing. Additionally, it sells certain immunoassay tests and reagents for insurance risk assessment, substance abuse testing, and forensic toxicology applications; an oral fluid Western blot HIV-1 confirmatory test for confirming positive HIV-1 test; and the FDA 510(k) cleared Q.E.D. rapid point-of-care saliva alcohol test. The company sells its products to various clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians’ offices, and commercial and industrial entities in the United States and internationally. OraSure Technologies, Inc. was founded in 1979 and is based in Bethlehem, Pennsylvania.

313 Employees
Last Reported Date: 03/13/13
Founded in 1979

orasure technologies inc (OSUR) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $548.8K
Chief Operating Officer, Chief Financial Offi...
Total Annual Compensation: $429.3K
Chief Science Officer and Executive Vice Pres...
Total Annual Compensation: $366.7K
Senior Vice President, General Counsel and Se...
Total Annual Compensation: $311.5K
Executive Vice President of Marketing and Sal...
Total Annual Compensation: $361.5K
Compensation as of Fiscal Year 2012.

orasure technologies inc (OSUR) Key Developments

OraSure Technologies Inc. Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2013; Provides Earnings Guidance for the Second Quarter of 2013

OraSure Technologies Inc. announced unaudited consolidated earnings results for the first quarter ended March 31, 2013. For the quarter, the company's net loss was $10.2 million, or $0.18 per basic and diluted share, which compares to a net loss of $3.3 million, or $0.07 per basic and diluted share, for the first quarter of 2012. Net revenues were $21.2 million compared with $20.9 million a year ago. Operating loss was $10.6 million compared with $3.7 million a year ago. Loss before income taxes was $10.6 million compared with $3.8 million a year ago. Capital expenditures were $0.48 million compared with $0.31 million a year ago. Cash used in operating activities was $7.7 million compared with $1.4 million a year ago. The company expects consolidated net revenues to range from $23.5 to $24.0 million and is projecting a consolidated net loss of approximately $0.15 - $0.16 per share for the second quarter of 2013.

OraSure Technologies Inc. to Report Q1, 2013 Results on May 08, 2013

OraSure Technologies Inc. announced that they will report Q1, 2013 results at 4:00 PM, US Eastern Standard Time on May 08, 2013

OraSure Technologies Inc., Q1 2013 Earnings Call, May 08, 2013

OraSure Technologies Inc., Q1 2013 Earnings Call, May 08, 2013

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
OSUR:US $4.34 USD -0.07

OSUR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Cornerstone Therapeutics Inc $8.46 USD +0.05
Derma Sciences Inc $14.01 USD +0.20
Nymox Pharmaceutical Corp $5.28 USD +0.05
Psychemedics Corp $11.40 USD -0.05
Sciclone Pharmaceuticals Inc $4.86 USD -0.11
View Industry Companies
 

Industry Analysis

OSUR

Industry Average

Valuation OSUR Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2.8x
Price/Book 1.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.9x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ORASURE TECHNOLOGIES INC, please visit www.orasure.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.